1236861-63-4 Usage
General Description
Tert-butyl 3-(quinolin-2-yl)azetidine-1-carboxylate is a chemical compound with the formula C18H22N2O2. It is a tert-butyl ester derivative of azetidine-1-carboxylic acid, substituted with a quinolin-2-yl group at the 3-position. tert-butyl 3-(quinolin-2-yl)azetidine-1-carboxylate has potential applications in medicinal chemistry, particularly in the development of new drugs and pharmaceuticals. Its unique structure and properties make it a valuable building block for synthesizing biologically active molecules and studying their interactions with biological targets. Additionally, its tert-butyl ester group provides stability and protection, making it a useful precursor for various synthetic transformations. The compound's molecular structure and properties make it an interesting target for further investigations in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 1236861-63-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,6,8,6 and 1 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1236861-63:
(9*1)+(8*2)+(7*3)+(6*6)+(5*8)+(4*6)+(3*1)+(2*6)+(1*3)=164
164 % 10 = 4
So 1236861-63-4 is a valid CAS Registry Number.
1236861-63-4Relevant articles and documents
PDE 10a Inhibitors for the Treatment of Type II Diabetes
-
Paragraph 0607; 0615-0616, (2015/01/06)
Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.
AMINO-HETEROCYCLIC COMPOUNDS
-
Page/Page column 22, (2010/08/07)
The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
